diethylpropion / Generic mfg. - LARVOL DELTA

Physiological and Behavioral Effects of Chronic Diethylpropion Exposure During Development in Caenorhabditis elegans: An In Vivo and in Silico Toxicity Approach. (PubMed, J Appl Toxicol) - "Diethylpropion (DEP), a psychostimulant structurally related to amphetamine, is prescribed as an appetite suppressant but carries a potential risk of neurotoxicity and abuse. In silico analysis predicted high neurotoxicity, oxidative stress potential, and endocrine disruption, with probable interactions in dopaminergic signaling and mitochondrial function. These findings indicate that developmental DEP exposure disrupts multiple physiological systems in C. elegans, highlighting its potential to cause lasting neuromuscular and reproductive impairments."

Journal • Preclinical

Real-World Evidence of Diethylpropion Use in Patients with Severe Obesity in Indonesia: A Case Series (ECO 2026) - "Blood pressure reduction in these patients appeared to parallel decreases in body weight and fat mass. Although diethylpropion is contraindicated in individuals with moderate to severe hypertension or significant cardiovascular disease, its use may be considered with caution in patients with well-controlled hypertension under close clinical monitoring. Further large-scale, long-term randomized placebo-controlled trials are warranted to establish stronger evidence regarding the long-term efficacy and cardiovascular safety of diethylpropion in the treatment of morbid obesity, as well as to investigate its potential synergistic effects when combined with other therapeutic interventions."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Genetic Disorders • Hypertension • Obesity

Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder. (PubMed, JAMA Netw Open) - "Post-bariatric surgery treatment with an IBT (semaglutide, liraglutide, or tirzepatide) vs non-IBT AOMs (orlistat, phentermine, low-dose naltrexone, benzphetamine, phendimetrazine, or diethylpropion). These findings suggest potential neurobehavioral benefits associated with IBTs that may inform AOM selection in this high-risk population. Prospective studies are warranted to confirm these associations and examine long-term liver-related outcomes."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • Genetic Disorders • Obesity

Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration. (PubMed, JAMA Ophthalmol) - "Patients were prescribed either the GLP-1RAs liraglutide or semaglutide or OWLDs including lorcaserin, sibutramine, setmelanotide, fenfluramine, mazindol, orlistat, phentermine, and diethylpropion. In this cohort study, GLP-1RA use was associated with reduced risk of developing nonexudative AMD but was not associated with progression to exudative AMD among individuals with nonexudative AMD. These findings may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations."

Journal • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Genetic Disorders • Macular Degeneration • Metabolic Disorders • Obesity • Ophthalmology • Retinal Disorders

Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development. (PubMed, Am J Ophthalmol) - "GLP-1RA use was associated with a significantly reduced risk of age-related cataract compared to OWLD use and no pharmacologic treatment. These findings support the need for randomized prospective trials and mechanistic studies to better understand this observed association."

Journal • Cataract • Genetic Disorders • Metabolic Disorders • Obesity • Ophthalmology

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity

Drugs and devices for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison table: Some drugs for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Sex-specific effects of appetite suppressants on stereotypy in rats. (PubMed, PLoS One) - "However, in contrast, female rats demonstrated greater and more homogenous weight loss than males following the administration of diethylpropion and tesofensine...Analysis of motor side effects revealed that drugs primarily targeting dopamine pathways - specifically, phentermine, mazindol, diethylpropion, cathine, and d-amphetamine - induced pronounced stereotypies, particularly head-weaving, in both sexes...Network analysis and Markov transition matrices revealed distinct behavioral profiles associated with head-weaving, which emerged as the dominant attractor state, suggesting potential mechanistic differences among these drugs. Collectively, this study provides a valuable database characterizing the behavioral side effects of appetite suppressants."

Journal • Preclinical • Movement Disorders

AN ANALYSIS OF ANTI-OBESITY MEDICATION PRESCRIPTION RATE DISPARITIES IN THE ELDERLY POPULATION (DDW 2025) - "Medications considered were in accordance with the 2022 AGA Guidelines for Pharmacotherapy Management of Obesity – semaglutide, liraglutide, phentermine, phentermine-topiramate, naltrexone-bupropion, and diethylpropion from 11/16/2022 (following guideline publication) to 11/15/2024. The results of this study showed varied prescribing rates across age groups. Among patients with obesity aged 40-60 years, 0.8% were prescribed an AOM. This rate was higher compared to individuals aged 20-40 years at 0.5% (P<0.0001)."

Clinical • Diabetes • Genetic Disorders • Obesity

A simple method for the determination of stimulant substances in postmortem blood: development, validation, and application in nearly 1000 forensic cases. (PubMed, Forensic Toxicol) - "A rapid and straightforward LC-MS/MS method for the quantitative analysis of drugs in postmortem blood was validated and successfully applied to nearly 1000 postmortem blood samples."

Journal

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity • Oncology

Trends in the Prescription of Weight Loss Medications in Patients With Obesity: A Nationwide Cross-Sectional Analysis, 1999-2018 (ACG 2024) - "Prescription medication data included FDA-approved weight-loss drugs such as phentermine, sibutramine, diethylpropion, phentermine/topiramate, orlistat, bupropion/naltrexone, GLP-1 agonist. Weight-loss inducing anti-diabetic drugs included pramlintide, SGLT-2 inhibitors, metformin...The most prescribed FDA-approved medication was phentermine followed by liraglutide and orlistat... The proportion of subjects who met the criteria for receiving weight-loss drugs increased from 42.4% in 1999-2000 to 51.9% in 2017-2018. However, the use of FDA-approved drugs alone remained low ranging from 0.29% in 1999-2000 to 1.12% in 2017-2018. When anti-diabetes drugs with weight-loss effects were included, the proportion of use ranged from 5.16% in 1999-2000 to 14.24% in 2017-2018."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Obesity

Combination of diethylpropion with dietary intervention results in body weight and fat loss with preserved muscle mass in obese patients. (PubMed, Medicine (Baltimore)) - "This study revealed no significant changes in patient systolic and diastolic pressures despite showing mild increases after 70 days. The combination of diethylpropion and an appropriate diet resulted in weight loss accompanied by significant fat loss and preserved muscle mass without an increase in blood pressure during the 12-week treatment period."

Journal • Retrospective data • Genetic Disorders • Obesity

RISK OF CONSTIPATION WITH ANTI-OBESITY MEDICATION AND CURRENT PRESCRIBING PATTERN LANDSCAPE IN MANAGING THE SIDE EFFECT (DDW 2024) - "We then determined whether these patients were prescribed a medication for constipation (plecanatide linaclotide tegaserod lubiprostone polyethylene glycol (PEG) magnesium oxide lactulose bisacodyl senna sodium picosulfate tenapanor prucalopride)...8% (7/145) diethylpropion...Liraglutide and phentermine-topiramate had the highest constipation rates. Black patients had higher rate of new constipation diagnosis and treatment compared to White patients. Semaglutide had the least risk for requiring constipation medication."

Adverse events • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity

IMPLICATIONS OF POPULAR TRENDING ANTI-OBESITY MEDICATIONS - AN INCREASE IN HEALTHCARE COST AND UTILIZATION FOR THE POPULATION WITH CONSTIPATION (DDW 2024) - "Inclusion criteria included obese patients started on an AOM (per the 0 AGA Guideline on the Pharmacological Interventions for Adults with Obesity - semaglutide liraglutide phentermine-topiramate phentermine naltrexone-bupropion diethylpropion) who subsequently developed constipation after one week to twelve months after starting the AOM...The search was then narrowed to patients who were prescribed a constipation medication: plecanatide linaclotide tegaserod lubiprostone polyethylene glycol (PEG) magnesium oxide lactulose bisacodyl senna sodium picosulfate tenapanor prucalopride...Patients on AOM who develop constipation appear to have a threefold increase in ED visits and inpatient admissions. The average annual cost of constipation medication alone is $5 485. 04 per person."

Clinical • HEOR • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity

LOW PRESCRIPTION RATES OF ANTI-OBESITY MEDICATIONS AND BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH OBESITY COMPARED TO THE GENERAL POPULATION WITH OBESITY DESPITE NEW EFFECTIVE GLUCAGON LIKE PEPTIDE 1 (GLP-1) AGONISTS (DDW 2024) - "0% (14/1416) liraglutide 0...No patients with both IBD and obesity were prescribed phentermine-topiramate or diethylpropion...In conclusion IBD patients with obesity may be an overlooked patient population for AOM treatments as well as surgical intervention. Barriers to prescribing and offering these therapies and impact on outcomes needs to be studied."

Bariatric surgery • Clinical • Surgery • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Obesity • Ulcerative Colitis

A SHIFT IN PRESCRIBING PATTERNS OF ANTI-OBESITY MEDICATIONS - AN ASSESSMENT OF EVIDENCE-BASED PRACTICE IMPLEMENTATION (DDW 2024) - "Liraglutide rose from 1 3 to 1 549 ( 7%). Phentermine-topiramate increased 107 to 138 ( 9%)...Finally diethylpropion increased 56 to 67 ( 0%)...Since guideline publication in October 0 all races and genders saw an increase in AOM prescription rates. The largest racial disparity was in the Asian population (3. 5%) prior and (7."

Gastroenterology • Genetic Disorders • Obesity

Weight loss medication prescription prevalence in the active component, 2018-2023. (PubMed, MSMR) - "The findings indicate a significant rise in the period prevalence of weight loss prescriptions over time. Further research is recommended to assess the effectiveness, safety, and use in austere military environments."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=24 | Recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Feb 2024 ➔ Sep 2024

Inflammatory cell • Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity • Oncology

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. (PubMed, Gastroenterology) - "In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options."

Clinical guideline • Cardiovascular • Gastroenterology • Genetic Disorders • Obesity

The Protective Effects and Mechanism of Doxepin on Radiation-Induced Lung Injury in Rats. (PubMed, Dose Response) - "Further, histological examinations showed doxepin could tenuate the radiation injury, as indicated as alveolar inflammatory exudation and there was only mild interstitial inflammation infiltration. Western blotting and q-PCR showed that expression of NF-κβ in X group were higher than that in XMD group. For the first time, we reported doxepin functioned as a radioprotectant candidate, which provide a promising application of doxepin for protecting radiotherapy injuries."

Journal • Preclinical • Immunology • Inflammation • Respiratory Diseases • CRP

Comparison table: Some FDA-approved drugs for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

FDA event • Journal

Drugs and devices for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

"Drs @PDavitkov & @ruben_hernaez present 💊 Pharm Mgmt of Obesity @blakely_md @apoorvachandar The @AmerGastroAssn suggests using 🔸semaglutide 🔸liraglutide 🔸phentermine-topiramate ER 🔸naltrexone-bupropion 🔸diethylpropion And suggests *against* 🔸orlistat" (,@ShaziaMSiddique)

Genetic Disorders • Obesity